These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12359587)

  • 21. Simultaneous intravitreal injection of triamcinolone acetonide and tissue plasminogen activator for central retinal vein occlusion: a pilot study.
    Yamamoto T; Kamei M; Sayanagi K; Matsumura N; Nishida K; Sakaguchi H; Tsujikawa M; Tano Y
    Br J Ophthalmol; 2011 Jan; 95(1):69-73. PubMed ID: 20494908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study.
    Elman MJ
    Trans Am Ophthalmol Soc; 1996; 94():471-504. PubMed ID: 8981710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion.
    Shortell CK; Queiroz R; Johansson M; Waldman D; Illig KA; Ouriel K; Green RM
    J Vasc Surg; 2001 Nov; 34(5):854-9. PubMed ID: 11700486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retinal vein cannulation with prolonged infusion of tissue plasminogen activator (t-PA) for the treatment of experimental retinal vein occlusion in dogs.
    Tameesh MK; Lakhanpal RR; Fujii GY; Javaheri M; Shelley TH; D'Anna S; Barnes AC; Margalit E; Farah M; De Juan E; Humayun MS
    Am J Ophthalmol; 2004 Nov; 138(5):829-39. PubMed ID: 15531319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intravenous thrombolysis with rt-PA in stroke: experience of the French military hospital of Toulon from September 2003 to June 2009].
    Faivre A; Sagui E; Canini F; Wybrecht D; Bounolleau P; Grapperon J; Alla P; Valance J
    Rev Neurol (Paris); 2010 Nov; 166(11):909-20. PubMed ID: 20452634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stroke in the puerperium treated with intra-arterial rt-PA.
    Rønning OM; Dahl A; Bakke SJ; Hussain AI; Deilkås E
    J Neurol Neurosurg Psychiatry; 2010 May; 81(5):585-6. PubMed ID: 20460599
    [No Abstract]   [Full Text] [Related]  

  • 28. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents.
    Collen D; Stump DC; Van de Werf F
    Am Heart J; 1986 Nov; 112(5):1083-4. PubMed ID: 3096127
    [No Abstract]   [Full Text] [Related]  

  • 29. Updated cannulation technique for tissue plasminogen activator injection into peripapillary retinal vein for central retinal vein occlusion.
    van Overdam KA; Missotten T; Spielberg LH
    Acta Ophthalmol; 2015 Dec; 93(8):739-44. PubMed ID: 26310993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intravenous thrombolysis beyond the 3h time window after stroke onset and in stroke patients after 80 years and older].
    Neundörfer B
    Fortschr Neurol Psychiatr; 2007 Jun; 75(6):315. PubMed ID: 17549660
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude.
    Roy S
    J Vasc Interv Radiol; 2001 Feb; 12(2):264-6. PubMed ID: 11265895
    [No Abstract]   [Full Text] [Related]  

  • 33. [Rt-PA thrombolysis in the treatment of massive pulmonary embolism].
    Van Hover P; Stockx L; Raat H; Vervloessem I; Vandenbosch G; Verhaeghe R; Baert AL
    J Belge Radiol; 1996 Nov; 79(5):208-10. PubMed ID: 8984107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study.
    Glacet-Bernard A; Kuhn D; Vine AK; Oubraham H; Coscas G; Soubrane G
    Br J Ophthalmol; 2000 Jun; 84(6):609-13. PubMed ID: 10837386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intravitreal tissue plasminogen activator for treatment of central retinal vein occlusion associated with diabetic retinopathy].
    Suzuma K; Murakami T; Watanabe D; Miyamoto K; Kita M; Takagi H; Yoshimura N
    Nippon Ganka Gakkai Zasshi; 2009 Apr; 113(4):492-7. PubMed ID: 19455970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombolysis in acute ischemic stroke.
    Lang W; Domanovits H; Görzer H; Germann P; Gatterbauer E; Segall B
    Acta Anaesthesiol Scand Suppl; 1997; 111():34-7. PubMed ID: 9420947
    [No Abstract]   [Full Text] [Related]  

  • 37. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion.
    Lahey JM; Fong DS; Kearney J
    Ophthalmic Surg Lasers; 1999 Jun; 30(6):427-34. PubMed ID: 10392729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Timing error.
    Rocher E
    Nursing; 1997 Jan; 27(1):6. PubMed ID: 9016075
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen].
    Maksimenko AV; Tishchenko EG; Petrova ML; Golubykh VL
    Biull Eksp Biol Med; 1996 Jan; 121(1):48-51. PubMed ID: 8680005
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.